Primary Structure Characterization
Online Inquiry
Structural characterization of antibody drugs is an important part of pharmacological studies in the pre-clinical phase of drug declaration. The structure of an antibody determines the function, and the correct structure plays a decisive role in the efficacy and biological activity of an antibody drug. The primary structural characterization of antibody drugs is essential to understand their stability, specificity and functionality. Creative Proteomics uses peptide mapping, N-terminal sequencing, C-terminal sequencing and other related technologies to perform a comprehensive structural characterization of antibody drugs.
Peptide mapping is a widely used technique in primary structure characterization. It involves the enzymatic digestion of an antibody into smaller peptides followed by their separation and identification using various analytical techniques. This approach provides valuable information about the location of post-translational modifications (PTMs), disulfide bridges, and potential degradation sites within the antibody structure.
The process of peptide mapping typically begins with the reduction and alkylation of disulfide bonds in the antibody, followed by enzymatic digestion using proteases such as trypsin or chymotrypsin. The resulting peptides are then analyzed using liquid chromatography (LC) coupled with mass spectrometry (MS) to identify and quantify the peptides.
N-terminal sequencing is a valuable service that focuses on determining the identity of the first amino acid in the protein chain. It plays a critical role in confirming the correct translation initiation site and identifying any signal peptides present. Creative Proteomics performs N-terminal sequencing using automated Edelman degradation, which selectively removes contiguous amino acids from the N-terminus of proteins and identifies them using LC-MS/MS or liquid chromatography-tandem mass spectrometry.
C-terminal sequencing is an essential technique used in the characterization of antibody drugs. Antibody drugs are proteins that are designed to specifically target disease-causing molecules in the body. Understanding the sequence of the C-terminal region of these antibodies is crucial as it helps in determining the identity and integrity of the protein. C-terminal sequencing offered by Creative Proteomics involves identifying the last few amino acid residues at the end of the antibody molecule. This information provides valuable insights into post-translational modifications, such as glycosylation or truncation, which can affect the stability and efficacy of the antibody drug. By employing C-terminal sequencing, researchers can verify the correct assembly of the antibody's heavy and light chains, ensuring the production of therapeutically effective drugs.
Sequence confirmation service for antibody drugs is a vital step in the development and manufacturing of these therapeutics. It involves the verification and confirmation of the correct amino acid sequence of the antibody to ensure its safety and efficacy. Creative Proteomics uses advanced analytical techniques to accurately determine the amino acid sequence and identify any potential sequence variations or modifications.
De Novo sequencing is a technique used to sequence the entire genetic makeup of an organism, including its DNA or RNA. In the context of antibody drugs, De Novo sequencing is used to identify and analyze the complete amino acid sequence of the antibody. Creative Proteomics is pleased to launch of De Novo sequencing service for antibody drugs. This cutting-edge service combines the latest advancements in DNA sequencing technology with our expertise in antibody drug development to provide accurate and reliable sequencing results.
Creative Proteomics offers primary structural characterization services that help clients gain a comprehensive understanding of the primary structure, modifications, and key attributes of antibody therapeutics, contributing to their safety, efficacy, and overall quality. Contact us to learn more about our primary structural characterization services for antibody drugs. We will be happy to assist you.
